CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010
REVENUE:
Commercial revenue	$ 9,881,533	$ 2,836,587	$ 19,904,312	$ 6,618,626
Developmental revenue	11,895,607	4,219,274	22,725,783	13,130,714
Total revenue	21,777,140	7,055,861	42,630,095	19,749,340
OPERATING EXPENSES:
Cost of chemicals sold	2,405,493	329,629	2,650,695	646,666
Research and development	6,079,433	5,760,105	18,186,043	16,089,409
Selling, general and administrative	4,957,085	3,452,815	13,324,863	9,719,643
Patent costs	1,938,143	1,177,383	5,466,245	2,802,549
Royalty and license expense	461,917	218,474	881,956	507,094
Total operating expenses	15,842,071	10,938,406	40,509,802	29,765,361
Operating income (loss)	5,935,069	(3,882,545)	2,120,293	(10,016,021)
INTEREST INCOME	363,700	64,373	644,050	201,153
INTEREST EXPENSE	(13,263)	(5,957)	(31,331)	(18,664)
GAIN (LOSS) ON STOCK WARRANT LIABILITY	239,562	(3,362,441)	(4,190,283)	(5,231,626)
INCOME (LOSS) BEFORE INCOME TAX EXPENSE	6,525,068	(7,186,570)	(1,457,271)	(15,065,158)
INCOME TAX (EXPENSE) BENEFIT	(535,642)		(1,121,459)	464,162
NET INCOME (LOSS)	$ 5,989,426	$ (7,186,570)	$ (2,578,730)	$ (14,600,996)
NET INCOME (LOSS) PER COMMON SHARE:
Basic	$ 0.13	$ (0.19)	$ (0.06)	$ (0.39)
Diluted	$ 0.12	$ (0.19)	$ (0.06)	$ (0.39)
WEIGHTED AVERAGE SHARES USED IN COMPUTING NET INCOME (LOSS) PER COMMON SHARE:
Basic	45,314,893	37,741,107	43,101,933	37,380,190
Diluted	46,799,557	37,741,107	43,101,933	37,380,190